Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04700722 · ClinicalTrials.gov registry record
Synuclein-One Study
A clinical trial of Parkinson Disease and Multiple System Atrophy, sponsored by CND Life Sciences.
- Completed
- Registry status
- 428
- Enrollment target
- 20
- Study locations
NCT04700722: Completed study of Parkinson Disease and Multiple System Atrophy, sponsored by CND Life Sciences.
NCT04700722 is a study of Parkinson Disease and Multiple System Atrophy that has completed, run by CND Life Sciences. The registered enrollment target is 428 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04700722, a study of Parkinson Disease and Multiple System Atrophy, has completed, sponsored by CND Life Sciences.
- COMPLETED
- Registry status
- 428 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.
Primary Outcome
To define test accuracy and precision of skin biopsy detection of phosphorylated α-synuclein.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Skin Biopsy
Study Locations (20)
Florida
- Aventura Neurology - Aventura
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- UF College of Medicine - Gainesville
- Parkinson's Disease Treatment Center SWFL - Port Charlotte
Arizona
- MD First Research - Chandler
- CND Life Sciences - Phoenix
- Movement Disorders Center of Arizona - Scottsdale
California
- The Neuro Center - Carlsbad
- Providence St. John's Health - Santa Monica
Massachusetts
- Boston Medical Center - Boston
- Beth Israel Lahey Health - Boston
New York
- NYU Medical Center - New York
- SouthShore Neurologic - Patchogue
Colorado
- Rocky Mountain Movement Disorders Center, PC - Englewood
Illinois
- NorthShore University Health System - Evanston
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 428 participants |
| Start Date | 2021-01-04 |
| Est. Completion | 2023-11-08 |
What the finished NCT04700722 record still lists
NCT04700722 is an observational study that tracks outcomes without assigning an intervention. The registered 428 participants enrollment target is mid-sized for trials with a published cap, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (92% lower).
The record links to 4 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Skin Biopsy is the first listed.
NCT04700722 names 20 study sites across 12 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04700722 about?
NCT04700722 is a clinical study titled "Synuclein-One Study". The Synuclein-One Study will be evaluating α-synuclein in patients with Parkinson's disease, Multiple System Atrophy, Dementia with Lewy bodies and Pure Autonomic Failure. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodeg...
What is the current status of trial NCT04700722?
This trial is currently completed. The enrollment target is 428 participants. The study started on 2021-01-04. Estimated completion is 2023-11-08.
What conditions does trial NCT04700722 study?
This clinical trial studies the following conditions: Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Pure Autonomic Failure.
What interventions are being tested in trial NCT04700722?
The interventions under investigation include: Skin Biopsy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04700722?
This trial is sponsored by CND Life Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04700722 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04700722's enrollment target sits among peer trials
428 27th of 297 higher than 271 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05566431 · 428 participants · NA
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
- NCT05646316 · 428 participants · Phase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- NCT05797610 · 428 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- NCT06073626 · 428 participants · NA
Addressing Genomic Disparities in Cancer Survivors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI